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Background: Current guidelines recommend pretreatment with a loading dose of clopidogrel before the procedure to reduce the incidence of peri-
procedural myocardial infarctions in patients undergoing PCI. However, due to concerns about post-CABG bleeding, clopidogrel loading is frequently 
administered either immediately before or after the PCI.
Methods: Using the 2004/2005 Cornell Angioplasty Registry, we analyzed 1,041 consecutive patients undergoing urgent PCI for UA/NSTEMI. 
Patients were divided into 2 groups: (1) “pre-angiography clopidogrel therapy”: those on chronic 75-mg clopidogrel therapy or receiving clopidogrel 
loading (300-mg ≥12 hrs or 600-mg ≥2 hrs) pre-PCI according to guidelines; (2) “in-lab 600-mg clopidogrel loading”: <2 hours pre-PCI 
(immediately before or after the PCI). Mean clinical follow-up was 23.8 ± 7.6 months.
Results: Of the 1,041 study patients, there were 467 (44.9%) patients receiving clopidogrel pre-angiography and 574 (55.1%) patients receiving 
in-laboratory loading. DES were used in 88% of PCI, 40% of patients presented with NSTEMI. The incidence of in-hospital death (0.4% vs. 0.5%, 
p=1.000), post-procedural MI (7.7% vs. 6.8, p=0.630), and MACE including death, stroke, emergent CABG/PCI, and MI (8.4% vs. 7.1%, p=0.484) 
were similar in the “pre-angiography therapy” group versus “in-lab 600-mg clopidogrel loading” group, respectively. Kaplan-Meier long-term survival 
rates were similar in those receiving clopidogrel pre-angiography versus those loaded with 600-mg of clopidogrel in the lab (93.4% vs. 95.8%, p log 
rank=0.152). After multivariate Cox analysis, administration of 600-mg clopidogrel load <2 hours pre-PCI did not have a significant impact on long-
term mortality (HR 0.97, 95%CI 0.54-1.75, p=0.927).
Conclusions: Treatment with a 600-mg loading dose <2 hours pre-PCI is associated with similar short-term ischemic outcomes and long-term 
mortality when compared to currently recommended clopidogrel pretreatment regimen. These results suggest that a strategy of high-dose 600-mg 
clopidogrel loading once coronary anatomy has been defined may be a safe and practical alternative to conventional clopidogrel loading pre-
angiography.
